Stiripentol May Help Some Children With Severe Epilepsy

Source: Pediatric neurology

Summary

This paper reviewed research on stiripentol, a seizure medicine, in children with developmental and epileptic encephalopathies, or DEEs. DEEs are severe childhood seizure disorders that often come with delays in development and problems with thinking, behavior, or mental health. The review focused on children with DEEs other than Dravet syndrome, since stiripentol is already approved for Dravet syndrome in children 6 months and older who also take clobazam.

Overall, the studies suggested that adding stiripentol was linked with better seizure control in some children with non-Dravet DEEs. In different study groups, children had fewer seizures, some became seizure-free, and some had fewer episodes of status epilepticus, which is a dangerous long seizure emergency. A few studies also reported possible gains in thinking or development. The medicine was generally described as having a favorable safety and tolerability profile.

This matters because children with DEEs often have seizures that are hard to control, and these conditions can strongly affect both the child and the family. The review suggests stiripentol may help some children beyond its current approved use in Dravet syndrome. But the evidence is still limited: the paper summarizes earlier studies rather than testing the drug in a new trial, and the studies included different DEE diagnoses and patient groups, which makes the results less certain.

Original source